A new trading data show Nabriva Therapeutics plc (NBRV) is showing positive returns.

Nabriva Therapeutics plc (NASDAQ: NBRV) stock jumped 8.72% on Friday to $0.20 against a previous-day closing price of $0.18. With 1.2 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.81 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.2100 whereas the lowest price it dropped to was $0.1800. The 52-week range on NBRV shows that it touched its highest point at $1.40 and its lowest point at $0.16 during that stretch. It currently has a 1-year price target of $2.00. Beta for the stock currently stands at 1.49.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NBRV was up-trending over the past week, with a rise of 12.38%, but this was up by 4.95% over a month. Three-month performance dropped to -35.62% while six-month performance fell -61.45%. The stock lost -83.85% in the past year, while it has lost -67.11% so far this year. A look at the trailing 12-month EPS for NBRV yields -0.94 with Next year EPS estimates of -0.40. For the next quarter, that number is -0.20. This implies an EPS growth rate of 78.90% for this year and 50.70% for next year.

Float and Shares Shorts:

At present, 58.79 million NBRV shares are outstanding with a float of 55.59 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.57 million, which was 0.89% higher than short shares on Jun 14, 2022. In addition to Mr. Theodore R. Schroeder as the firm’s CEO & Director, Dr. Steven P. Gelone Pharm. D serves as its Pres, COO & Director.

Institutional Ownership:

Through their ownership of 13.46% of NBRV’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 3.77% of NBRV, in contrast to 1.83% held by mutual funds. Shares owned by individuals account for 1.49%. As the largest shareholder in NBRV with 2.13% of the stake, Fidelity Management & Research Co holds 1,343,459 shares worth 1,343,459. A second-largest stockholder of NBRV, Medical Strategy GmbH, holds 468,994 shares, controlling over 0.74% of the firm’s shares. Renaissance Technologies LLC is the third largest shareholder in NBRV, holding 393,794 shares or 0.62% stake. With a 1.78% stake in NBRV, the Fidelity Advisor Series I -Growth is the largest stakeholder. A total of 1,126,502 shares are owned by the mutual fund manager. The FCP Medical – BioHealth, which owns about 0.64% of NBRV stock, is the second-largest Mutual Fund holder. It holds 406,307 shares valued at 73948.0. Acatis Datini Valueflex Fonds holds 0.55% of the stake in NBRV, owning 350,189 shares worth 63734.0.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NBRV since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NBRV analysts setting a high price target of $2.00 and a low target of $2.00, the average target price over the next 12 months is $2.00. Based on these targets, NBRV could surge 900.0% to reach the target high and rise by 900.0% to reach the target low. Reaching the average price target will result in a growth of 900.0% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. NBRV will report FY 2022 earnings on 03/16/2023. Analysts have provided yearly estimates in a range of -$0.73 being high and -$0.73 being low. For NBRV, this leads to a yearly average estimate of -$0.73. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Nabriva Therapeutics plc surprised analysts by -$0.01 when it reported -$0.20 EPS against a consensus estimate of -$0.19. The surprise factor in the prior quarter was -$0.05. Based on analyst estimates, the high estimate for the next quarter is -$0.20 and the low estimate is -$0.20. The average estimate for the next quarter is thus -$0.20.

Summary of Insider Activity:

Insiders traded NBRV stock several times over the past three months with 0 Buys and 10 Sells. In these transactions, 0 shares were bought while 1,278 shares were sold. The number of buy transactions has increased to 3 while that of sell transactions has risen to 50 over the past year. The total number of shares bought during that period was 157,000 while 20,200 shares were sold.

Leave a Comment

Your email address will not be published.